Mapping individual multiple myeloma biology to understand relapse and treatment resistance
MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity
This project will test whether combining clinical records with whole-genome and RNA sequencing plus blood tumor markers in people with multiple myeloma can reveal features that explain relapse and treatment resistance.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 520 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna, Bo) |
| Trial ID | NCT07582354 on ClinicalTrials.gov |
What this trial studies
This is a single-center, observational effort enrolling adults with monoclonal gammopathy or active multiple myeloma, conducted retrospectively and prospectively. The study links detailed clinical data with advanced molecular analyses, including whole-genome sequencing, RNA sequencing, and circulating tumor markers. Samples and data will be securely stored and analyzed to identify biological and clinical factors tied to disease progression and therapy response. The aim is to build a comprehensive map of disease heterogeneity to inform more personalized treatment approaches in the future.
Who should consider this trial
Good fit: Adults (18+) with a diagnosis of monoclonal gammopathy or active multiple myeloma (newly diagnosed, relapsed, or refractory) who can give informed consent and provide required samples are the ideal candidates.
Not a fit: Patients seeking an immediate change in their therapy or those unable to travel to the Bologna site or provide samples should not expect direct therapeutic benefit from participation.
Why it matters
Potential benefit: If successful, the findings could help doctors tailor treatments and detect likely relapse or resistance earlier for future patients.
How similar studies have performed: Prior genomic and molecular profiling studies in multiple myeloma have identified meaningful subgroups and predictors of outcome, but comprehensive integrated whole-genome plus longitudinal circulating marker mapping remains an emerging approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18+ * Signed CI for study partecipation and personal data processing. * Diagnosis of monoclonal gammopathy, or of acrive multiple myaloma (NDMM/RMM/RRMM) Exclusion Criteria: * None
Where this trial is running
Bologna, Bo
- IRCCS AOU Policlinico Sant'Orsola — Bologna, Bo, Italy (Recruiting)
Study contacts
- Study coordinator: Carolina Terragna, MD
- Email: carolina.terragna@unibo.it
- Phone: 0512143831
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.